세계의 암 면역치료 시장 예측(2025-2030년)

The global cancer immunotherapy market is expected to grow from USD 167.862 billion in 2025 to USD 341.273 billion in 2030, at a CAGR of 15.25%.

The global cancer immunotherapy market is experiencing robust growth, driven by the increasing prevalence of cancer and advancements in therapies that harness the body's immune system to combat cancer cells. Immunotherapy leverages natural defense mechanisms to identify and eliminate cancer, offering targeted treatment options with reduced toxicity compared to traditional methods. The market is propelled by significant investments in research and development, growing adoption of advanced therapies, and rising cancer awareness. However, high treatment costs and lengthy regulatory approval processes pose challenges to market expansion. Despite these hurdles, the market is poised for continued growth, particularly in regions with strong healthcare infrastructure and emerging economies with rising cancer incidences.

Key Growth Drivers

Investments in Advanced Immunotherapies

The cancer immunotherapy market is bolstered by substantial investments from major pharmaceutical companies and research organizations. These investments focus on developing targeted immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, which enhance efficacy and minimize side effects. Collaborative efforts among industry leaders are accelerating the development of novel drugs, driving market growth by addressing unmet needs in cancer treatment and improving patient outcomes.

Rising Incidence of Lung Cancer

The increasing prevalence of lung cancer, driven by factors such as smoking and environmental exposures, significantly contributes to market growth. Lung cancer holds a substantial share of the immunotherapy market due to its high global incidence. The adoption of immunotherapies, supported by high healthcare expenditure in developed economies and ongoing research into effective treatments, is expected to further propel demand, particularly for lung cancer-specific therapies.

Market Segmentation

By Application

The cancer immunotherapy market is segmented into skin cancer, lung cancer, leukemia, bladder cancer, and others. Lung cancer dominates due to its high prevalence and the growing adoption of immunotherapies in regions with strong healthcare systems. Bladder cancer and leukemia also hold significant shares, driven by increased research and development investments targeting these cancer types, which require specialized immunotherapeutic approaches to improve patient outcomes.

By Geography

The market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. North America is expected to maintain a significant market share, driven by early adoption of innovative therapies, a high prevalence of cancer, and substantial R&D investments. The presence of key market players and a robust regulatory framework, including FDA approvals for immunotherapy drugs, further supports growth. Asia-Pacific is projected to experience rapid growth, fueled by an increasing cancer patient pool, rising awareness, and technological advancements in countries like India and China, where clinical trials for therapies like CAR-T are expanding.

Competitive Landscape

Key players, including Bristol-Myers Squibb Company, Eisai Co., Ltd., Nektar, and Servier, are driving innovation through collaborative research and development of advanced immunotherapies. These companies focus on novel drug combinations and targeted therapies to enhance treatment efficacy and expand market reach.

The cancer immunotherapy market is set for significant growth, propelled by rising cancer incidences, particularly lung cancer, and substantial investments in advanced therapies. North America leads due to its strong healthcare infrastructure, while Asia-Pacific's rapid expansion reflects growing patient needs and clinical advancements. Despite challenges like high costs and regulatory delays, the market's trajectory remains positive, driven by ongoing innovation and the critical role of immunotherapy in transforming cancer treatment.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2020 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

The global cancer immunotherapy market has been analyzed through the following segments:

By Type

• Monoclonal antibodies (MABs)
• Checkpoint Inhibitors
• Cytokines
• Cancer vaccines
• Adoptive Cell Transfer

By Application

• Melanoma
• Lung Cancer
• Leukemias
• Bladder Cancer
• Breast Cancer
• Colorectal Cancer
• Others

By End User

• Hospitals and Clinics
• Cancer Research Centers
• Canada

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• Italy
• United Kingdom
• Others
• Middle East and Africa
• Israel
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL CANCER IMMUNOTHERAPY MARKET BY TYPE

• 5.1. Introduction
• 5.2. Monoclonal antibodies (MABs)
• 5.3. Checkpoint Inhibitors
• 5.4. Cytokines
• 5.5. Cancer vaccines
• 5.6. Adoptive Cell Transfer

6. GLOBAL CANCER IMMUNOTHERAPY MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Melanoma
• 6.3. Lung Cancer
• 6.4. Leukemias
• 6.5. Bladder Cancer
• 6.6. Breast Cancer
• 6.7. Colorectal Cancer
• 6.8. Others

7. GLOBAL CANCER IMMUNOTHERAPY MARKET BY END USER

• 7.1. Introduction
• 7.2. Hospitals and Clinics
• 7.3. Cancer Research Centers

8. GLOBAL CANCER IMMUNOTHERAPY MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. Italy
  • 8.4.4. United Kingdom
  • 8.4.5. Others
• 8.5. Middle East & Africa
  • 8.5.1. Israel
  • 8.5.2. Saudi Arabia
  • 8.5.3. UAE
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. South Korea
  • 8.6.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Servier
• 10.2. Sanofi
• 10.3. Xencor
• 10.4. Pfizer Inc.
• 10.5. Cellectis SA
• 10.6. CytomX Therapeutics, Inc.
• 10.7. Bristol-Myers Squibb Company
• 10.8. Nektar
• 10.9. Eisai Co., Ltd.
• 10.10. Merck & Co., Inc.
• 10.11. F. Hoffmann-La Roche Ltd.

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations